Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape

Research output: Contribution to journalArticle

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive-fibrosing interstitial lung disease of unknown origin that affects 3 million people worldwide and imparts substantial burdens to patients, their families, and the healthcare system. The IPF disease course is highly variable and presents several diagnostic and management-related challenges. Two therapies, nintedanib and pirfenidone, are FDA approved and are recommended by clinical practice guidelines for the treatment of IPF. Although neither of these treatments is curative, both slow disease progression and impact survival of patients with IPF. To ensure optimal management, this supplement will provide an overview of the epidemiology, pathophysiology, and diagnosis of IPF, along with management-based considerations including evidence-based guideline recommendations, in-depth reviews of nintedanib and pirfenidone, and outcomes from other completed clinical trials.

Original languageEnglish (US)
Pages (from-to)S195-S203
JournalThe American journal of managed care
Volume25
Issue number11
StatePublished - Jul 1 2019

Fingerprint

Idiopathic Pulmonary Fibrosis
Guidelines
Therapeutics
Interstitial Lung Diseases
Practice Guidelines
Lung Diseases
Disease Progression
Epidemiology
Clinical Trials
Delivery of Health Care
Survival

ASJC Scopus subject areas

  • Health Policy

Cite this

@article{b8d45009abf94b8281acf8890eaa767d,
title = "Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive-fibrosing interstitial lung disease of unknown origin that affects 3 million people worldwide and imparts substantial burdens to patients, their families, and the healthcare system. The IPF disease course is highly variable and presents several diagnostic and management-related challenges. Two therapies, nintedanib and pirfenidone, are FDA approved and are recommended by clinical practice guidelines for the treatment of IPF. Although neither of these treatments is curative, both slow disease progression and impact survival of patients with IPF. To ensure optimal management, this supplement will provide an overview of the epidemiology, pathophysiology, and diagnosis of IPF, along with management-based considerations including evidence-based guideline recommendations, in-depth reviews of nintedanib and pirfenidone, and outcomes from other completed clinical trials.",
author = "{Glassberg Csete}, {Marilyn K}",
year = "2019",
month = "7",
day = "1",
language = "English (US)",
volume = "25",
pages = "S195--S203",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "11",

}

TY - JOUR

T1 - Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape

AU - Glassberg Csete, Marilyn K

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive-fibrosing interstitial lung disease of unknown origin that affects 3 million people worldwide and imparts substantial burdens to patients, their families, and the healthcare system. The IPF disease course is highly variable and presents several diagnostic and management-related challenges. Two therapies, nintedanib and pirfenidone, are FDA approved and are recommended by clinical practice guidelines for the treatment of IPF. Although neither of these treatments is curative, both slow disease progression and impact survival of patients with IPF. To ensure optimal management, this supplement will provide an overview of the epidemiology, pathophysiology, and diagnosis of IPF, along with management-based considerations including evidence-based guideline recommendations, in-depth reviews of nintedanib and pirfenidone, and outcomes from other completed clinical trials.

AB - Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive-fibrosing interstitial lung disease of unknown origin that affects 3 million people worldwide and imparts substantial burdens to patients, their families, and the healthcare system. The IPF disease course is highly variable and presents several diagnostic and management-related challenges. Two therapies, nintedanib and pirfenidone, are FDA approved and are recommended by clinical practice guidelines for the treatment of IPF. Although neither of these treatments is curative, both slow disease progression and impact survival of patients with IPF. To ensure optimal management, this supplement will provide an overview of the epidemiology, pathophysiology, and diagnosis of IPF, along with management-based considerations including evidence-based guideline recommendations, in-depth reviews of nintedanib and pirfenidone, and outcomes from other completed clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85071580555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071580555&partnerID=8YFLogxK

M3 - Article

C2 - 31419091

AN - SCOPUS:85071580555

VL - 25

SP - S195-S203

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 11

ER -